<DOC>
	<DOCNO>NCT00672399</DOCNO>
	<brief_summary>This Phase 1 , randomize , three period , placebo- positive-controlled , double-blind , double-dummy , crossover study perform approximately 80 healthy male female subject . The effect single dos exenatide ( 10 μg , subcutaneous ) , moxifloxacin ( 400 mg , oral ) placebo ( subcutaneous oral ) QT interval assess .</brief_summary>
	<brief_title>Electrophysiological Effects Single 10 μg Dose Exenatide 12-Lead Electrocardiogram QT Interval Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>Fluoroquinolones</mesh_term>
	<mesh_term>Norgestimate , ethinyl estradiol drug combination</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<criteria>Are age 18 65 year , inclusive . Have body mass index ( BMI ) 19 35 kg/m2 , inclusive . If female , childbearing potential due surgical sterilisation ( hysterectomy bilateral oophorectomy tubal ligation ) menopause . Women intact uterus deem postmenopausal cessation menses least 1 year 6 12 month spontaneous amenorrhea follicle stimulate hormone &gt; 40 IU/mL ; age ≥45 year ; take oral contraceptive least 1 year ; otherwise healthy . Subjects receive hormone replacement therapy ( HRT ) thyroxine replacement therapy may participate provide stable therapy least 3 month normal thyroid stimulate hormone ( TSH ) value . Have receive treatment within last 30 day drug receive regulatory approval indication time study entry . Known allergy exenatide excipients , moxifloxacin related compound , history multiple adverse drug allergy origin . Family history sudden death . Personal history unexplained syncope within last year . History presence cardiovascular ( myocardial infarction , cerebrovascular accident , venous thromboembolism ) , respiratory , hepatic , renal , GI , endocrine , haematological , neurological disorder . Evidence history Long QT Syndrome significant active cardiac disease ( e.g. , arrhythmia , hypertension , congestive heart failure , hypokalaemia , mitral valve regurgitation , endocarditis , coronary artery heart disease ) , symptoms angina pectoris transient ischaemic attack within previous 6 month . Females lactate . Have previously complete withdrawn study study investigate exenatide . Evidence human immunodeficiency virus ( HIV ) and/or positive human HIV antibody . Evidence hepatitis C and/or positive hepatitis C antibody . Evidence hepatitis B and/or positive hepatitis B surface antigen . Use overthecounter prescription medication ( , example , thyroid replacement , occasional intake paracetamol , vitamin mineral supplement ) 7 14 day , respectively , dose throughout study . Cumulative blood donation 500 mL within last 3 month . Subjects average weekly alcohol intake exceed 28 unit per week ( male ) 21 unit per week ( female ) , subject unwilling stop alcohol consumption duration study ( 1 unit = 12 oz 360 mL beer ; 5 oz 150 mL wine ; 1.5 oz 45 mL distilled spirit ) . Subjects smoke smoke within 28 day screen visit unable abide study restriction .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Amylin</keyword>
	<keyword>Eli Lilly</keyword>
	<keyword>exenatide</keyword>
	<keyword>moxifloxacin</keyword>
</DOC>